Citations

Clear

2960 citation(s) found for "Kim, P".

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study
Al-Modhwahi, Ibrahim, Andersen, Mette Klarskov , Behrendtz, Mikael, Forestier, Erik, Hasle, Henrik , Heyman, Mats , Kristinsson, Jón, Nersting, Jacob , Nygaard, Randi, Svendsen, Anne Louise, Vettenranta, Kim , Weinshilboum, Richard M. , Schmiegelow, Kjeld , Weinshilboum, Richard M.

Mayo Clinic

Blood | February 17, 2009 | Volume: 113 | Issue: 24 | Pages: 6077-6084

10.1182/blood-2008-11-187880 | PMID 19224761 Get It

Abstract Among 1614 children with acute lymphoblastic leukemia (ALL) treated with the Nordic Society for Paediatric Haematology and Oncology (NOPHO) ALL-92 protocol, 20 patients developed a second malignant neoplasm (SMN) with a cumulative risk of 1.6% at 12 years from the diagnosis of ALL. Nine of the 16 acute myeloid leukemias or myelodysplastic syndromes had monosomy 7 (n = 7) or 7q deletions (n = 2). In Cox multivariate analysis, longer duration of oral 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy (P = .02; longest for standard-risk patients) and presence of high hyperdiploidy (P = .07) were related to increased risk of SMN. Thiopurine methyltransferase (TPMT) methylates 6MP and its metabolites, and thus reduces cellular levels of cytotoxic 6-thioguanine nucleotides. Of 524 patients who had erythrocyte TPMT activity measured, the median TPMT activity in 9 patients developing an SMN was significantly lower than in the 515 that did not develop an SMN (median, 12.1 vs 18.1 IU/mL; P = .02). Among 427 TPMT wild-type patients for whom the 6MP dose was registered, those who developed SMN received higher average 6MP doses than the remaining patients (69.7 vs 60.4 mg/m2; P = .03). This study indicates that the duration and intensity of 6MP/MTX maintenance therapy of childhood ALL may influence the risk of SMNs in childhood ALL.
Interposition graft with polytetrafluoroethylene for mesenteric and portal vein reconstruction after pancreaticoduodenectomy
Stauffer, John , Dougherty, Marjorie K., Kim, G.P., Nguyen, Justin H. , A Stauffer, John

Mayo Clinic

British Journal of Surgery | February 17, 2009 | Volume: 96 | Issue: 3 | Pages: 247-252

10.1002/bjs.6483 | PMID 19224515 Get It

Abstract Background Portal vein–superior mesenteric vein resection is frequently required after surgical resection of tumours of the pancreas head. The ideal graft for portal vein reconstruction (PVR) remains undefined. Methods Between May 2000 and July 2007, 28 patients had portal vein–superior mesenteric vein resection and PVR during pancreaticoduodenectomy. Their clinical reports were reviewed retrospectively with specific attention to the methods of PVR and outcomes. Results Ten patients had PVR with primary anastomosis, seven had PVR with autologous vein, one had a polytetrafluoroethylene (PTFE) patch, one did not have PVR and nine had PVR with a PTFE interposition graft. There was no infection after PTFE grafting. Six patients had PVR thrombosis after surgery: four after primary anastomosis, one after interposition PTFE and one after vein repair. Conclusion PTFE appeared to be an effective and safe option as an interposition graft for portomesenteric venous reconstruction after pancreaticoduodenectomy.
Three-Dimensional Porous Biodegradable Polymeric Scaffolds Fabricated with Biodegradable Hydrogel Porogens
Kim, Jinku , Yaszemski, Michael J. , Lu, Lichun

Mayo Clinic

Tissue Engineering Part C: Methods | February 13, 2009 | Volume: 15 | Issue: 4 | Pages: 583-594

10.1089/ten.tec.2008.0642 | PMID 19216632 Get It

Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma
Kim, Jinhee, Jonasch, Eric, Short, John D., Cai, Shengli , Wen, Sijin , Tsavachidou, Dimitra, Tamboli, Pheroze, Wu, Kevin J. , Marlow, Laura A. , Wood, Christopher G. , Copland, John A. , Walker, Cheryl L. , Kim, Jinhee, Alexander, Angela , Czerniak, Bogdan A. , Do, Kim‐Anh , Marlow, Laura

Mayo Clinic

Clinical Cancer Research | December 31, 2008 | Volume: 15 | Issue: 1 | Pages: 81-90

10.1158/1078-0432.ccr-08-0170 | PMID 19118035 Get It

Abstract Purpose: p27 localization and expression has prognostic and predictive value in cancer. Little is known regarding expression patterns of p27 in renal cell carcinoma (RCC) or how p27 participates in disease progression or response to therapy. Experimental Design: RCC-derived cell lines, primary tumors, and normal renal epithelial cells were analyzed for p27 expression, phosphorylation (T157 of the NLS), and subcellular localization. RCC-derived cell lines were treated with phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitors and effects on p27 localization were assessed. The potential contribution of cytoplasmic p27 to resistance to apoptosis was also evaluated. Results: p27 was elevated in tumors compared with matched controls, and cytoplasmic mislocalization of p27 was associated with increasing tumor grade. Cytoplasmic localization of p27 correlated with phosphorylation at T157, an AKT phosphorylation site in the p27 NLS. In RCC cell lines, activated PI3K/AKT signaling was accompanied by mislocalization of p27. AKT activation and phosphorylation of p27 was associated with resistance to apoptosis, and small interfering RNA knockdown of p27 or relocalization to the nucleus increased apoptosis in RCC cells. Treatment with the PI3K inhibitors LY294002 or wortmannin resulted in nuclear relocalization of p27, whereas mTOR inhibition by rapamycin did not. Conclusions: In RCC, p27 is phosphorylated at T157 of the NLS, with increasing tumor grade associated with cytoplasmic p27. PI3K inhibition (which reduces AKT activity) reduces T157 phosphorylation and induces nuclear relocalization of p27, whereas mTOR inhibition does not. Clinical testing of these findings may provide a rational approach for use of mTOR and PI3K/AKT pathway inhibitors in patients with RCC.
Atypical Rheumatoid Nodules: A Possible Precursor to a Rheumatoid Variant in a Rheumatoid-Factor-Negative Patient. Case Report
Kim, Sharon , Parker, Wendy L., Beckenbaugh, Robert D.

Mayo Clinic

HAND | December 1, 2008 | Volume: 4 | Issue: 1 | Pages: 62-65

10.1007/s11552-008-9146-7 | PMID 19048351 Get It

Subcutaneous nodules occur in approximately 20–25% of rheumatoid factor (RF)-positive rheumatoid patients. In this paper, we present a unique case of a 47-year-old healthy RF-negative woman with a 3-year history of necrobiotic nodules over the dorsum of her hands, extensor forearms, and lower extremities. This may represent an atypical presentation or a new rheumatoid variant.
Evidence for Enhanced Thy-1 (CD90) Expression in Orbital Fibroblasts of Patients with Graves' Ophthalmopathy
Khoo, Teck Kim, Coenen, Michael J., Schiefer, A, Kumar, Seema , Bahn, Rebecca S.

Mayo Clinic

Thyroid | November 3, 2008 | Volume: 18 | Issue: 12 | Pages: 1291-1296

10.1089/thy.2008.0255 | PMID 18976167 Get It

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Johnson, David C. , Corthals, Sophie L., Ramos, Christine, Hoering, Antje , Cocks, Kim , Dickens, Nicholas J. , Haessler, Jeff, Goldschmidt, H., Child, J. Anthony, Bell, Sue , Jackson, Graham , Baris, Dalsu , Rajkumar, S. Vincent , Davies, Faith E. , Durie, Brian G.M. , Crowley, John, Sonneveld, Pieter , Ness, Brian Van, Morgan, Gareth J. , Rajkumar, S Vincent , Davies, Faith E , Morgan, Gareth J

Mayo Clinic

Blood | September 20, 2008 | Volume: 112 | Issue: 13 | Pages: 4924-4934

10.1182/blood-2008-02-140434 | PMID 18805967 Get It

AbstractA venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in the treatment of patients with multiple myeloma with thalidomide. The susceptibility to developing a VTE in response to thalidomide therapy is likely to be influenced by both genetic and environmental factors. To test genetic variation associated with treatment related VTE in patient peripheral blood DNA, we used a custom-built molecular inversion probe (MIP)–based single nucleotide polymorphism (SNP) chip containing 3404 SNPs. SNPs on the chip were selected in “functional regions” within 964 genes spanning 67 molecular pathways thought to be involved in the pathogenesis, treatment response, and side effects associated with myeloma therapy. Patients and controls were taken from 3 large clinical trials: Medical Research Council (MRC) Myeloma IX, Hovon-50, and Eastern Cooperative Oncology Group (ECOG) EA100, which compared conventional treatments with thalidomide in patients with myeloma. Our analysis showed that the set of SNPs associated with thalidomide-related VTE were enriched in genes and pathways important in drug transport/metabolism, DNA repair, and cytokine balance. The effects of the SNPs associated with thalidomide-related VTE may be functional at the level of the tumor cell, the tumor-related microenvironment, and the endothelium. The clinical trials described in this paper have been registered as follows: MRC Myeloma IX: ISRCTN68454111; Hovon-50: NCT00028886; and ECOG EA100: NCT00033332.
Effect of level of presentation on scaled speech intelligibility of speakers with dysarthria
Kim, Yunjung , Weismer, Gary, Kent, Raymond D. , Duffy, Joseph R.

Mayo Clinic

The Journal of the Acoustical Society of America | September 9, 2008 | Volume: 122 | Issue: 5_Supplement | Pages: 3028-3028

10.1121/1.2942828 Get It

A considerable amount of effort has been made to seek the acoustic correlates of reduced speech intelligibility in dysarthria, although some acoustic variables are under debate: For example, articulation rate, F2 slope, and vowel space have been frequently discussed in previous studies as acoustic predictors of speech intelligibility of dysarthria [Kim (2007)]. One variable that is not well understood, with respect to its effect on speech intelligibility in dysarthria, is level of presentation. This includes level generated by a speaker as well as level of presentation after the speaker has recorded utterances. Clearly, variations in level of presentation of recorded utterances will have some effect when an intelligibility test requires some segmental analysis (as in a minimal pairs test), but the potential effect when speech intelligibility is scaled is not so clear. This is an important question because of the frequent use of scaled intelligibility in dysarthria research. In this presentation, we will report data on how scaled speech intelligibility is affected by level of presentation of speech samples produced by speakers with various types and severity of dysarthria. [Work supported by NIH DC00319.]
Gender-Related Difference in Left Ventricular Diastolic Elastance During Exercise in Patients With Diabetes Mellitus
Ha, Jong‐Won , Park, Sungha , Choi, Eui‐Young , Seo, Hye-Sun, Shim, Chi Young , Ahn, Jeong‐Ah , Lee, Se-Wha, Rim, Se‐Joong , Oh, Jae K. , Chung, Namsik, Lee, Hyun‐Chul , Kim, Jin‐Man

Mayo Clinic

Circulation Journal | August 25, 2008 | Volume: 72 | Issue: 9 | Pages: 1443-1448

10.1253/circj.cj-07-1028 | PMID 18724019 Get It